CONCLUSIONS: Among people who have opioid use disorder, mental disorders are associated with poorer retention in buprenorphine treatment from 6 months. The small number of cohorts within each analysis emphasises a further need for studies examining the association between mental disorders and buprenorphine or methadone retention. This review highlights the importance of clinicians in assessing for comorbid mental disorders to facilitate appropriate long-term care and improve treatment outcomes.
